Microcap Ledger Caribou Biosciences, Inc. $CRBU
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Berkeley, CA
- Fiscal year end
- December 31
- Shares outstanding
- 107,207,513 [10-Q 2026-08-13]
What the company doesAI summary of filing
Caribou Biosciences is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using its proprietary CRISPR chRDNA genome-editing technology. The company is advancing two product candidates in clinical trials: vispa-cel, an anti-CD19 CAR-T therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma. Caribou does not currently generate revenue and is funding its clinical development programs through equity financing and strategic partnerships, with anticipated continued operating losses as it pursues regulatory approval and potential commercialization of its product candidates. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $3.90M | −$49.37M | −$49.77M | $26.19M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $11.16M | −$148.13M | −$110.99M | $12.36M | [10-K 2026-03-05] |
| FY ended Dec 2024 | $9.99M | −$149.10M | −$138.20M | $16.29M | [10-K 2026-03-05] |
- Quarterly cash burn
- −$24.89M
- Cash runway Estimate
- ~3.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 90,552,687 | [10-Q 2024-11-06] |
| 2025-03-04 | 93,004,602 | [10-K 2025-03-10] |
| 2025-05-02 | 93,004,602 | [10-Q 2025-05-08] |
| 2025-08-05 | 93,123,239 | [10-Q 2025-08-12] |
| 2025-11-03 | 93,468,038 | [10-Q 2025-11-12] |
| 2026-02-27 | 96,637,202 | [10-K 2026-03-05] |
| 2026-04-30 | 99,180,575 | [10-Q 2026-05-07] |
| 2026-08-07 | 107,207,513 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2025-05-08; declared effective 2025-05-14 [S-3 2025-05-08]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-02-25 | Kelly Timothy P | sell | 6,228 | $1.93 | [4 2026-02-27] |
| 2026-02-24 | Kelly Timothy P | sell | 3,147 | $1.96 | [4 2026-02-24] |
| 2026-02-24 | Mcclung Barbara G | sell | 6,938 | $1.96 | [4 2026-02-24] |
| 2026-02-24 | Khan Ruhi Ahmad | sell | 6,938 | $1.96 | [4 2026-02-24] |
| 2026-02-24 | Albertson Tina M. | sell | 1,066 | $1.96 | [4 2026-02-24] |
| 2026-02-20 | Kelly Timothy P | grant | 45,000 | — | [4 2026-02-24] |
| 2026-02-20 | Mcclung Barbara G | grant | 45,000 | — | [4 2026-02-24] |
| 2026-02-20 | Khan Ruhi Ahmad | grant | 45,000 | — | [4 2026-02-24] |
| 2026-02-20 | Albertson Tina M. | grant | 55,000 | — | [4 2026-02-24] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Exit or disposal costs; Director or officer change; Regulation FD disclosure |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-07-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-18 | 8-K | Shareholder vote results |
| 2026-06-11 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-24 | DEF 14A | Proxy statement |
| 2026-04-10 | PRE 14A | Proxy statement |
| 2026-03-31 | 8-K | Regulation FD disclosure; Other events |
| 2026-03-05 | 10-K | Annual report |
Alerts for $CRBU
Email me when Caribou Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.